Mr. Andre Larente reports

DIAGNOS ANNOUNCES A PILOT WITH OPTICALIA IN SPAIN

Diagnos Inc. has signed for a pilot in Spain with three franchisees from Opticalia Group.

"A proposal that combines optometrist knowledge, telemedicine and artificial intelligence to obtain fast results, without invasive methodology and with totally reliable results. A smart retinography is also used, which, once the patient is positioned, it automatically searches for the retina in the eye. All the techniques used in this process are non-invasive, painless and quick for the comfort and tranquility of the patient," states Elsa Tortosa, owner and head of optometrists for the Opticalia franchise in Pinoso, Spain.

Meanwhile, in the cities of Aspe and Novelda, Spain, Santos Diaz, head of optometrists and owner of Opticalia franchises, who has been in the sector for 23 years innovating and transforming his optics into the new business model oriented to health in general and visual in particular, says: "The campaign begins with the request for a previous appointment through the Web or at the optician itself, where patients will register in order of arrival and a free retinography will be carried out. With the results we obtain, a prediagnosis of their fundus will be made with respect to diabetic retinopathy."

The councillor for health in the Aspe city council, Yolanda Moreno, stressed that this initiative will produce important data concerning the eye health for all Aspenses. "Thanks to Opticalia Aspe, our neighbours will be able to benefit from a treatment prediagnosis that allows detection of visual problems in a timely manner."

Opticalia Aspe is investing, on its own initiative, 6,000 euros in this campaign to detect and stop preventable blindness. "One of the tools used in this diagnostic process is based on artificial intelligence, a resource that comes from Diagnos, an international company located in Canada with extensive experience and with more than 400,000 retinographies performed around the world. This allows the precision of diabetic retinopathy prediagnoses to be very high, reaching a sensitivity of 98.4 per cent, specificity of 97.6 per cent and a certainty of 97.9 per cent. Data that improves human diagnoses under the same conditions, without applying drops to dilate the pupil and in four seconds, which is known as non-mydriatic retinography," said Andre Larente, president of Diagnos.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence (AI) platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.